IBRUTINIB COMBINED WITH BENDAMUSTINE/RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): FIRST RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY

被引：0
|
作者：
Cramer, P.
Chanan-Khan, A. [1 ]
Demirkan, F. [2 ]
Fraser, G. [3 ]
Santucci Silva, R. [4 ]
Pylypenko, H. [5 ]
Grosicki, S. [6 ]
Janssens, A. [7 ]
Pristupa, A. [8 ]
Mayer, J. [9 ]
Dilhuydy, M. S. [10 ]
Loscertales, J. [11 ]
Bartlett, N. L. [12 ]
Avigdor, A. [13 ,14 ]
Rule, S. [15 ]
Sun, S. [16 ]
Mahler, M. [16 ]
Salman, M. [16 ]
Howes, A. [17 ]
Hallek, M. [18 ,19 ]
机构：
[1] Mayo Clin, IL-52621 Jacksonville, FL USA
[2] Dokuz Eylul Univ, Juravinski Canc Ctr, IL-69978 Izmir, Turkey
[3] McMaster Univ, Hemomed Oncol & Hematol, Hamilton PL6 8DH, ON, Canada
[4] IEP SAO LUCAS, Dept Hematol, Sao Paulo, Brazil
[5] Cherkassy Reg Oncol Ctr, Fac Publ Hlth, Dept Canc Prevent, Cherkassy, Ukraine
[6] Silesian Med Univ, D-50931 Katowice, Poland
[7] Univ Ziekenhuizen Leuven, D-50931 Leuven, Belgium
[8] Reg Clin Hosp, Dept Internal Med Hematol & Oncol, Ryazan, Russia
[9] Univ Hosp Brno, Brno, Czech Republic
[10] Hop Haut Leveque, Hematol Dept, IIS IP, Pessac, France
[11] Hosp Univ La Princesa, Sch Med, Siteman Canc Ctr, Madrid, Spain
[12] Washington Univ, Div Hematol & Bone Marrow Transplantat, St Louis, MO USA
[13] Chaim Sheba Med Ctr, Sackler Sch Med, Tel Hashomer, Israel
[14] Tel Aviv Univ, Dept Haematol, Tel Aviv, Israel
[15] Derriford Hosp, Plymouth, Devon, England
[16] Janssen Res & Dev LLC, Raritan, NJ USA
[17] Janssen Res & Dev, Dept Internal Med 1, High Wycombe, Bucks, England
[18] Univ Cologne, Ctr Integrated Oncol, Cologne, Germany
[19] Univ Cologne, Cologne, Germany
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
LB218
引用
收藏
页码：55 / 56
页数：2
相关论文
共 50 条
  • [21] SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine plus Rituximab (BR) in Patients with Treatment-Naive (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Tam, Constantine S.
    Giannopoulos, Krzysztof
    Jurczak, Wojciech
    Simkovic, Martin
    Shadman, Mazyar
    Osterborg, Anders
    Laurenti, Luca
    Walker, Patricia
    Opat, Stephen
    Chan, Henry
    Ciepluch, Hanna
    Greil, Richard
    Tani, Monica
    Trneny, Marek
    Brander, Danielle M.
    Flinn, Ian W.
    Grosicki, Sebastian
    Verner, Emma
    Brown, Jennifer R.
    Kahl, Brad S.
    Ghia, Paolo
    Tian, Tian
    Marimpietri, Carol
    Paik, Jason C.
    Cohen, Aileen
    Huang, Jane
    Robak, Tadeusz
    Hillmen, Peter
    BLOOD, 2021, 138
  • [22] Ofatumumab and bendamustine in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma
    Ujjani, Chaitra
    Ramzi, Pari
    Gehan, Edmund
    Wang, Hongkun
    Wang, Yiru
    Cheson, Bruce D.
    LEUKEMIA & LYMPHOMA, 2015, 56 (04) : 915 - 920
  • [23] Comparing Single-Agent Ibrutinib, Bendamustine Plus Rituximab (BR) and Ibrutinib Plus BR in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): An Indirect Comparison of the RESONATE and HELIOS Trials
    Hillmen, Peter
    Fraser, Graeme
    Jones, Jeffrey
    Rule, Simon
    O'Brien, Susan
    Dilhuydy, Marie Sarah
    Jaeger, Ulrich
    Grosicki, Sebastian
    Cymbalista, Florence
    Sun, Steven
    Ninomoto, Joi
    Mahler, Michelle
    Cheng, Mei
    Diels, Joris
    Clow, Fong
    Salman, Mariya
    James, Danelle F.
    Howes, Angela
    Chanan-Khan, Asher
    BLOOD, 2015, 126 (23)
  • [24] Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): A Case Study
    Nanni, Danielle
    JOURNAL OF DIAGNOSTIC MEDICAL SONOGRAPHY, 2024, 40 (03) : 289 - 293
  • [25] Rituximab as first-line and maintenance therapy for patients with small lymphocytic lymphoma (SLL) and chronic lymphocytic leukemia (CLL).
    Hainsworth, JD
    Litchy, S
    Burris, HA
    Greco, FA
    BLOOD, 2001, 98 (11) : 363A - 363A
  • [26] First Interim Analysis of ALPINE Study: Results of a Phase 3 Randomized Study of Zanubrutinib vs Ibrutinib in Patients With Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Brown, Jennifer R.
    Hillmen, Peter
    Eichhorst, Barbara
    Lamanna, Nicole
    O'Brien, Susan
    Tam, Constantine S.
    Qiu, Lugui
    Kazmierczak, Maciej
    Zhou, Keshu
    Simkovic, Martin
    Mayer, Jiri
    Gillespie-Twardy, Amanda
    Shadman, Mazyar
    Ferrajoli, Alessandra
    Ganly, Peter S.
    Weinkove, Robert
    Salmi, Tommi
    Wu, Kenneth
    Novotny, William
    Jurczak, Wojciech
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S266 - S266
  • [27] Incidence of Autoimmune Cytopenias (AIC) in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL) Patients (pts) Treated with Ibrutinib
    Rogers, Kerry A.
    Woyach, Jennifer A.
    Andritsos, Leslie A.
    Awan, Farrukh
    Blum, Kristie A.
    Flynn, Joseph M.
    Jaglowski, Samantha
    Lozanski, Gerard
    Maddocks, Kami J.
    Byrd, John C.
    Jones, Jeffrey A.
    BLOOD, 2014, 124 (21)
  • [28] Activity and Tolerability of Ibrutinib in Combination With Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Jaglowski, Samantha M.
    Jones, Jeffrey A.
    Flynn, Joseph M.
    Andritsos, Leslie A.
    Maddocks, Kami J.
    Woyach, Jennifer A.
    Blum, Kristie A.
    Greyer, Michael R.
    Geyer, Susan Michelle
    Heerema, Nyla A.
    Lozanski, Gerard
    Stefanos, Mona
    Hall, Nathan
    Nagar, Veena
    Munneke, Brian
    West, Jamie-Sue
    Neuenburg, Jutta K.
    James, Danelle F.
    Johnson, Amy J.
    Byrd, John C.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S206 - S207
  • [29] A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)
    Furman, Richard R.
    Sharman, Jeff P.
    Coutre, Steven E.
    Cheson, Bruce D.
    Pagel, John M.
    Hillmen, Peter
    Barrientos, Jacqueline C.
    Zelenetz, Andrew D.
    Kipps, Thomas J.
    Flinn, Ian
    Ghia, Paolo
    Eradat, Herbert
    Ervin, Thomas
    Lamanna, Nicole
    Hallek, Michael
    Coiffier, Bertrand
    Pettitt, Andrew R.
    Ma, Shuo
    Stilgenbauer, Stephan
    Cramer, Paula
    Aiello, Maria
    Johnson, Dave M.
    Miller, Langdon L.
    Li, Daniel
    Jahn, Thomas M.
    Dansey, Roger D.
    O'Brien, Susan M.
    BLOOD, 2013, 122 (21)
  • [30] Phase II Study of Acalabrutinib and HighFrequency Low-Dose Subcutaneous Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
    Wallace, Danielle S.
    Baran, Andrea M.
    Friedberg, Jonathan W.
    Reagan, Patrick M.
    Casulo, Carla
    Friend, Mijamin
    Williams, Alyssa R.
    Dakin, Peter D.
    Zent, Clive S.
    Barr, Paul M.
    BLOOD, 2021, 138
12345